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Summary  
The Centers for Disease Control and Prevention (CDC) is expecting a 3 to 10 month nationwide shortage 
of APLISOL®, a product of Par Pharmaceuticals. APLISOL® is one of two purified-protein derivative 
(PPD) tuberculin antigens that are licensed by the United States Food and Drug Administration (FDA) for 
use in performing tuberculin skin tests. The manufacturer notified CDC that they anticipate a supply 
interruption of APLISOL® 5 mL (50 tests) beginning in June 2019, followed by a supply interruption of 
APLISOL® 1 mL (10 tests) in November 2019. The expected shortage of APLISOL® 1 mL (10 tests) 
could occur before November 2019, if demand increases before then. The 3-10 month timeframe for the 
nationwide shortage is the manufacturer’s current estimate and is subject to change. 
 
To monitor the status of this supply interruption, visit FDA’s “Center for Biologics Evaluation and 
Research (CBER)-Regulated Products: Current Shortages” webpage: https://www.fda.gov/vaccines-
blood-biologics/safety-availability-biologics/cber-regulated-products-current-shortages. 
 
Background 
Two types of immunological methods are used for detecting Mycobacterium tuberculosis infection: 
tuberculin skin tests (TSTs) and interferon-gamma release assay (IGRA) blood tests. TSTs and IGRAs 
are used for diagnosing latent TB infection and may aid in diagnosing TB disease. Additional evaluation 
and testing is necessary to distinguish between latent TB infection and TB disease, and to determine the 
correct treatment (1). When findings, such as chest radiography and mycobacterial cultures, are sufficient 
for confirming or excluding the TB diagnosis, the results from a TST or an IGRA blood test might not be 
needed (1). Most TB cases in the United States are diagnosed with a set of findings including results from 
one of these tests.  
 
Two FDA-approved PPD tuberculin antigens are available in the United States for use in performing 
TSTs: TUBERSOL® and APLISOL®. In controlled studies, the concordance between the two products is 
high (2). 
 
When TB disease is strongly suspected, specific treatment should be started regardless of results from 
TST or an IGRA blood test (3,4). 
 
Recommendations 
CDC recommends three general approaches to prevent a decrease in TB testing capability because of 
the expected shortage of APLISOL®. 
 Substitute IGRA blood tests for TSTs. Clinicians who use the IGRA blood tests should be aware 
that the criteria for test interpretation are different from the criteria for interpreting TSTs (3). 
 Substitute TUBERSOL® for APLISOL® for skin testing. In cross-sectional studies, the two skin 
test products give similar results for most patients.  
 Prioritize allocation of TSTs, in consultation with state and local public health authorities. 
Prioritization might require the deferment of testing some persons. CDC recommends testing only 
for persons who are at risk of TB (5-7). High-risk groups for TB infection include: 
o People who are recent contacts exposed to persons with TB disease;  
o People born in or who frequently travel to countries where TB disease is common; 
o People who currently or used to live in large group settings, such as homeless shelters or 
correctional facilities; 
o People with weaker immune systems, such as those with certain health conditions or 
taking certain medications that may alter immunity; and 
o Children, especially those under age 5, if they are in one of the risk groups noted above. 
 
While overall test concordance is high, switching between PPD skin test products or between TSTs and 
blood tests in serial testing may cause apparent conversions of results from negative to positive or 
reversions from positive to negative. This may be due to inherent inter-product or inter-method 
discordance, rather than change in M. tuberculosis infection status (3,8). Clinicians should assess test 
results based on the person’s likelihood of infection and risk of progression to TB disease, if infected (1). 
 
In settings with a low likelihood of TB exposure, the deferment of routine serial testing should be 
considered in consultation with public health and occupational health authorities. Annual TB testing of 
health care personnel is not recommended unless there is a known exposure or ongoing transmission (8). 
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The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
international organizations. 
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